Aptose to Present at September Investor Conferences
Aptose Biosciences (Nasdaq: APTO; TSX: APS) has announced participation in two upcoming virtual conferences in September 2020. The H. C. Wainwright 22nd Annual Global Investment Conference is scheduled for September 14, 2020, at 2:30 PM EDT, while the Cantor Virtual Global Healthcare Conference will take place on September 17, 2020, at 10:00 AM EDT. The management team, led by Dr. William G. Rice, will present and discuss their innovative oncology therapies targeting hematologic malignancies. Webcasts are available through the Aptose website.
- None.
- None.
SAN DIEGO and TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the upcoming conferences in September 2020:
- H. C. Wainwright 22nd Annual Global Investment Conference
| Date: | Monday, September 14, 2020 |
| Time: | 2:30 PM EDT |
| Format: | Virtual - Presentation |
| Webcast: | Link |
- Cantor Virtual Global Healthcare Conference
| Date: | Thursday, September 17, 2020 |
| Time: | 10:00 AM EDT |
| Format: | Virtual – Fireside Chat |
| Webcast: | Link |
The audio webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live events.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and has received an IND allowance to conduct a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (MDS). For further information, please visit www.aptose.com
For further information, please contact:
Aptose Biosciences Inc.
Greg Chow
Executive Vice President, CFO
650-718-5028
gchow@aptose.com
SMP Communications
Susan Pietropaolo
201-923-2049
susan@smpcommunications.com
LifeSci Advisors, LLC
Dan Ferry, Managing Director
617-535-7746
Daniel@LifeSciAdvisors.com
FAQ
What is Aptose Biosciences planning for September 2020?
What are the dates and times for Aptose's virtual conferences?
Who will represent Aptose Biosciences at the conferences?
How can I access the webcasts for Aptose's presentations?
What is Aptose's focus in cancer treatment?
